Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is ...

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper ...

Dr Suchitra Sundaram describes critical disparities in DLBCL treatment, urging for equitable access to care and representation in clinical trials.

While the authors demonstrate an improvement in overall survival with ... diffuse large B-cell lymphoma; Len, lenalidomide; R, rituximab; R/R, relapsed/refractory; SCT, stem-cell transplant.

Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers BV combined with Len + R demonstrated significant improvements in overall survival (OS; 37% reduced risk of ...

Higher toxicity rates also occurred. SAN DIEGO — Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings achieved worse survival ...

17% had B-cell lymphoma, 17% had leukemia and 8% had Hodgkin lymphoma. The median age of participants was 47. By week four, the response rate with ELA026 was 100% in the frontline setting ...

Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment ... cytarabine has similar survival and relapses rates in acute myeloid leukemia ...

ECHELON-3 enrolled adults with relapsed or refractory diffuse large B-cell ... form of lymphoma. There were favorable outcomes for key secondary endpoints, progression-free survival (PFS) and ...